Bolt Biotherapeutics, Inc.

Bolt did not report quarterly revenue, EPS, or gross margin on this call. The main hard operational update was that BDC-3042 has advanced through the first three dose escalation cohorts without any dose-limiting toxicities, and the fourth dose level cohort is fully enrolled. Management said BDC-1001 dose escalation showed a 29% or 30% overall response rate, but that bar was not met in expansion cohorts, leading to discontinuation of the program. Following the refocus and approximately 50% workforce reduction, Bolt expects to extend cash runway into the second half of 2026 and said it is adequately capitalized to reach upcoming milestones. The company plans a safety and enrollment update for BDC-3042 in the second half of 2024 and aims to initiate a BDC-4182 clinical trial in 2025.

Willie Quinn framed the update as a deliberate strategic reset centered on focusing scarce resources on the highest-potential assets. He emphasized that Bolt’s mission is unchanged, but the company is leaning into a more concentrated pipeline around BDC-3042, BDC-4182, and collaborations with Genmab and Toray. His tone was measured but optimistic, stressing that the platform has improved materially and that the company is better positioned after learning from BDC-1001.

Randy Schatzman said the company will reduce its workforce by approximately 50% and also shrink the board by two directors as part of the restructuring. He said these actions, combined with the portfolio shift away from BDC-1001, are expected to extend cash runway into the second half of 2026. He also highlighted leadership continuity by moving Willie Quinn from CFO to CEO and himself into an advisory role.

Analysts focused on why BDC-1001 was cut, what the learnings were, and whether the new ISAC approach—especially the Claudin 18.2 program—can compete with ADCs and T-cell engagers. Management said the key trigger was that expansion cohorts did not reproduce the 30% ORR seen in dose escalation, even though the program had shown safety, biomarker activity, and some clinical activity. On BDC-4182, they argued the next-generation ISAC is more potent because of improvements to the TLR7/8 payload, antibody performance, and conjugation chemistry, and on BDC-3042 they said preclinical models support monotherapy activity but clinical efficacy is still unproven and will be determined at higher dose levels.